Atmo Biosciences

Atmo Biosciences is a commercial-stage diagnostics company focused on revolutionizing the assessment of gastrointestinal motility disorders. Its core technology is the Atmo Gas Capsule, an ingestible device that measures gases and other parameters directly within the GI tract to determine transit times. With FDA clearance secured in 2025 and a strong clinical publication record, the company is positioned to address a significant unmet need in the functional GI disorder market. Backed by a seasoned leadership team and a prestigious medical advisory board, Atmo is leveraging its proprietary sensing platform to improve diagnostic accuracy for common and debilitating gut conditions.

Ingestible wireless gas-sensing capsule that measures hydrogen, carbon dioxide, oxygen, temperature, and movement to determine location and transit times within the gastrointestinal tract.

Atmo competes in the GI motility diagnostics market against established standards like gastric emptying scintigraphy and the Medtronic SmartPill (which measures pH, pressure, temperature). Its primary differentiation is the direct measurement of luminal gases to determine location, offering a potentially more physiological and region-specific assessment. Other competitors include manometry systems and simpler transit tests like radiopaque markers.